Author: Kirsteen Maclean
The number of publications featuring assays that showcase the breadth of NeoGenomics’ clinical and scientific expertise has been growing exponentially, demonstrating the rising interest to empower and support oncologists, pathologists, and our pharma and biotech partners. Following a successful AACR 2023 conference in April (https://neogenomics.com/newsroom/blog/aacr-2023-recap), May proved to be extremely impactful in the scope and sheer volume of published articles leveraging for example, both validated and custom assays inclusive of Next-Gen Sequencing (https://www.nature.com/articles/s41591-023-02347-y), our proprietary MultiOmyx™ high-order multiplexing spatial methodology (https://www.nature.com/articles/s41467-023-38342-7) and IHC (https://www.nature.com/articles/s41416-023-02280-4). With one of the most comprehensive laboratory services menus available for oncology, we look forward to many more published scientific insights supporting clinical trials today.
For more information on all our peer-reviewed publications, please visit, NeoGenomics.com/newsroom/literature
